Human Genome Sciences, Inc. (HGSI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joseph wang who wrote (14)	8/2/1996 7:11:00 AM
From: pwl	of 1127

Joseph, You point out that a lot of work remains to be done on the Human Genome. Taken together with an interesting article in the Financial Times (30 July 1996, p.9 - the technology page) on the difficulties of linking specific genes to specific medical conditions (for example, heart disease may result from any number of combinations of genes, some influencing cholesterol levels, others blood pressure, etc), what does this mean in terms of the TIMING of drug-based revenue for HGSI and similar companies ? Is it possible to develop useful drugs based on genetic knowledge before the entire human genome is mapped ? The FT article states that due to the complexity of the issues concerned with, say, general heart disease, research is now being focused on rare conditions that may have "single gene" causes in order to help understanding. I imagine that the commercial market for gene-based treatments of these "rare" conditions will be modest - but should we look for such developments as early indicators of more remunerating progress ? Anyone else have views/expertise in this area? Thanks ! Paul

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next